Developing new drugs to target a cancer protein called STAT5
Official title: Small-molecule degraders of STAT5
Funded at University of Michigan at Ann Arbor · NIH-10915589 · Data updated 2026-11-12
This study is exploring a new way to help people with acute myeloid leukemia by developing small molecules that can target and break down a protein called STAT5, which is often too active in their cancer, with the hope of finding better treatment options.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Michigan at Ann Arbor NIH-funded |
| Lab location | 1 site (Ann Arbor, United States) |
| Project start | September 1, 2023 |
| Project end | August 31, 2028 |
| Funding year | 2024 |
| Award (this year) | $614,944 |
| NIH project number | 5R01CA282673-02 |
| Project ID | NIH-10915589 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients diagnosed with acute myeloid leukemia or other cancers characterized by hyperactive STAT5.
✕Less likely to help
Patients with cancers not associated with hyperactive STAT5 or those who do not have acute myeloid leukemia may not benefit from this research.
What this research studies
This research focuses on creating small-molecule degraders that can effectively target and degrade the STAT5 protein, which is often overactive in certain types of leukemia. By using a novel approach called induced protein degradation, the researchers aim to inhibit the function of STAT5, which has been difficult to target with traditional therapies. The study involves designing and testing these degraders in human cancer cell lines and animal models to assess their effectiveness in reducing cancer cell growth and promoting tumor regression. If successful, this research could lead to new treatment options for patients with acute myeloid leukemia and other cancers associated with hyperactive STAT5.
Why it matters
Potential benefit: If successful, this research could provide new, effective treatment options for patients suffering from acute myeloid leukemia and other cancers linked to STAT5.
How similar studies have gone: Other research has shown promise in targeting similar 'undruggable' proteins using induced protein degradation, suggesting potential for success in this approach.
Where this research is happening
-
University of Michigan at Ann Arbor
Ann Arbor, United States Active
Researchers
- Principal investigator: Wang, Shaomeng — University of Michigan at Ann Arbor
- Study coordinator: Wang, Shaomeng
Related research
Other NIH-funded projects on the same topics.
-
Expanding genetic testing for cancer risk in patients and families
This study is working to make it easier for cancer patients in Michigan to get genetic testing for cancer risk by improving how doctors gather family history and assess genetic risks, so that more people can receive the important evaluations they need.
-
HEARTS hypertension and diabetes care in Guatemala
This grant tests how well the HEARTS primary care model works in Guatemala to improve blood pressure and blood sugar control for patients.
-
Why the retina can sometimes heal itself and how we might help it heal
This NIH grant explores how inflammation and neural cells interact in the zebrafish retina to understand retinal neuron death and regeneration, with potential implications for human vision.
-
Integrated Heart Health: A HEARTS-based approach to hypertension and diabetes in Guatemala
A study tests a team-based, stepwise care model to improve blood pressure and blood sugar control for people with both hypertension and diabetes in Guatemala.
-
Understanding how work exposures and genes influence ALS risk
A study is building a long-term group of people at higher risk for ALS to see how their jobs, exposures at work, and genes together affect if and when the disease might develop.
-
An integrated mobile health program to reduce SAVA and mental health problems among female sex workers in Kenya
A new mobile health program aims to help female sex workers in Kenya avoid substance abuse, violence, HIV, and depression by delivering group therapy, online resources, and a peer discussion space.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.